Angiotech is a global specialty pharmaceutical and medical device company that discovers, develops, and markets innovative technologies and medical products primarily for local diseases or for complications associated with medical device implants, surgical interventions and acute injury. We are listed on both the TSX and NASDAQ stock exchanges (TSX: ANP, NASDAQ: ANPI). The company's initial lead product, the TAXUS® drug-eluting coronary stent - which was co-developed and is now sold by Boston Scientific Corporation - is implanted in over four million patients worldwide.
We develop our products using a proprietary and systematic discovery approach. We use our drug screening capabilities to identify new uses for known pharmaceutical compounds. We look for compounds that address the underlying biological causes of conditions that can occur concurrently with medical device implantation, surgery or acute trauma. Once appropriate drugs have been identified, we formulate the drug, or combination of drugs, with our portfolio of biomaterials and drug delivery technologies to develop a novel drug-eluting medical device or surgical implant.
We have patent protected our technology and many of our products and potential product candidates, and our portfolio of intellectual property developed, licensed or acquired includes over 250 issued U.S. patents and 230 pending U.S. patent applications as of December 2007.
Following the acquisition of American Medical Instruments Holdings, Inc. in 2006, Angiotech expanded beyond its strong R&D capabilities to encompass the manufacturing and marketing of a wide range of single use, specialty medical devices, focused on interventional, surgical and OEM markets. Angiotech is currently working to develop a portfolio of next-generation products including its innovative Quill™ SRS, which is a bidirectional, barbed wound-closure device. Today, Angiotech has several specialized direct sales and distribution organizations in the United States and the European Union, as well as significant manufacturing capabilities.
| || |
At Angiotech, we are redefining success by striving to create novel medical solutions that elevate the standard of care and improve people's lives
| || |
| || |
Angiotech Pharmaceuticals, Inc. is a full filing, reporting corporation with the United States Securities and Exchange Commission, ("SEC").
CIK # 1096481
Link to SEC filing information:
Link to SEC:
Angiotech Pharmaceuticals, Inc. is a publically traded corporation listed on NASDAQ under the symbol ANPI.
Link to ANPI Quote & News information:
Link to Nasdaq:
Thursday February 5, 2009, 12:42 pm EST
Angiotech's corporate partner, Boston Scientific, submits final modules to FDA for approval of second-generation small vessel and long lesion stents
Thursday January 29, 2009, 8:30 am EST
Angiotech's corporate partner, Boston Scientific, announces Japanese approval for TAXUS(R) Liberte(R) drug-eluting stent system
ibox information/work in process...